Dermata Therapeutics (DRMA) Q1 2025 earnings summary

Executive summary

• Report covers the quarter ended March 31, 2025, for a late-stage dermatology-focused biotech developing Spongilla-based therapies for skin diseases and aesthetics.

• Lead candidate XYNGARI™ met all co-primary endpoints in the Phase 3 STAR-1 acne trial, showing statistically significant efficacy and rapid onset of action after four weeks.

• Entered a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY for axillary hyperhidrosis, with a Phase 2a trial planned.

• Raised $8.8 million in Q1 2025 from private placement and warrant inducement financings.

• No product revenue generated; operations funded by equity and warrant financings.

Financial highlights

• Net loss for Q1 2025 was $2.3 million, an improvement from $3.1 million in Q1 2024.

• Operating expenses decreased to $2.3 million from $3.2 million year-over-year, driven by lower R&D and G&A costs.

• Cash and cash equivalents totaled $9.7 million as of March 31, 2025, up from $3.2 million at December 31, 2024.

• Accumulated deficit reached $68.0 million.

• Net loss per share (basic and diluted) was $(0.45) for Q1 2025, compared to $(7.06) for Q1 2024.

Outlook and guidance

• Cash runway expected to fund operations into Q1 2026; additional capital will be needed for continued development and commercialization.

• Plans to initiate a second Phase 3 trial (STAR-2) for XYNGARI™ by end of 2025, followed by a 9-month extension study.

• Ongoing focus on regulatory approval and potential commercialization of XYNGARI™ for acne.

• Preparations underway for DMT410 Phase 2a clinical study with Revance for axillary hyperhidrosis.